Table 1.
Patient characteristics
| Characteristic | No. of patients | % | |
|---|---|---|---|
| No. of enrolled |
15 |
100.0% |
|
| Age, y |
|
|
|
| |
Median |
56 |
|
| |
Range |
44-66 |
|
| Chemotherapy | |||
| |
neoadjuvant |
3 |
20.0% |
| |
adjuvant |
10 |
66.7% |
| |
palliative |
2 |
13.3% |
| tumor hormone receptor | |||
| |
ER(+), PR(+) |
5 |
33.3% |
| |
ER(+), PR(-) |
3 |
20.0% |
| |
ER(-), PR(+) |
1 |
6.7% |
| |
ER(-), PR(-) |
5 |
33.3% |
| |
not applicable |
1 |
6.7% |
| Her2/neu | |||
| |
Absent |
5 |
33.3% |
| |
1+ |
3 |
20.0% |
| |
2+ |
4 |
26.7% |
| |
3+ |
2 |
13.3% |
| |
not applicable |
1 |
6.7% |
| GCSF administration | |||
| |
Yes |
7 |
46.7% |
| |
No |
8 |
53.3% |
| pT stage* | |||
| |
pT1 |
3 |
20.0% |
| |
pT2 |
9 |
60.0% |
| |
pT3 |
0 |
0.0% |
| |
pT4 |
3 |
20.0% |
| pN stage* | |||
| |
pN0 |
6 |
40.0% |
| |
pN1 |
4 |
26.7% |
| |
pN2 |
3 |
20.0% |
| |
pN3 |
1 |
6.7% |
| |
not applicable |
1 |
6.7% |
| Tumor grade | |||
| |
grade 1 |
2 |
13.3% |
| |
grade 2 |
6 |
40.0% |
| |
grade 3 |
6 |
40.0% |
| |
not applicable |
1 |
6.7% |
| Distant metastases | |||
| |
Yes |
2 |
13.3% |
| |
No |
13 |
86.7% |
| Chemotherapy regimen | |||
| |
Anthracycline-based |
7 |
46.7% |
| |
Taxane-based |
7 |
46.7% |
| Others** | 2 | 13.3% | |
*pT, pN stage: according to definition of AJCC 7th edition staging system.
**Others include: liposomal doxorubicin, vinorelbine. ER: estrogen receptor; PR: progesterone receptor; GCSF: Granulocyte colony-stimulating factor.